Integrating Bispecific Antibodies into the Armamentarium Against DLBCL – CHS webinar
Zoom WebinarDr. Michael Crump Bispecific antibodies have emerged as potent new therapy for resistant aggressive lymphomas. Integration of this new class of immunotherapy agents into the DLBCL algorithm represents new opportunities and new challenges, including timing relative to other treatments in the relapsed setting, and the...